Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding CDP-1050 as a paradigm for the treatment of heart failure, satisfaction of the medical community and regulatory authorities as to the
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... August 4, 2015 According ... Research, titled, "World Cardiac Biomarker - Market Opportunities, ... would generate the revenue of $2,085.9 million by ... to 2020. Cardiac Troponins (T, I) would continue ... due to high sensitivity and specificity. ...
(Date:8/4/2015)... SAN CARLOS, Calif. , Aug. 4, 2015 /PRNewswire/ ... non-invasive genetic testing and the analysis of circulating cell-free ... its second quarter ended June 30, 2015 after the ... a conference call and webcast at 1:30 p.m. PT ... activities and financial outlook.Event:Natera,s Second Quarter 2015 Results Conference ...
(Date:8/3/2015)...  ArroGen Group, an integrated advanced forensic solutions ... (FMID) technology Aug. 2-8 at the International Association ... Calif. FMID, a new ... agents, district attorneys and government agencies to build ... By analyzing chemical residues on fingerprints taken from ...
(Date:8/3/2015)... ... , ... Nine field days to promote practices that improve soil health will ... Health Partnership , the field days will demonstrate how changing certain practices, such as ... income. , Brent Bible has practiced no-till farming and planted cover crops on his ...
Breaking Biology Technology:Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5Natera to Release Second Quarter 2015 Results on August 12, 2015 2ArroGen Previews New Fingerprint Molecular Identification Technology 2Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3
... - Cytochroma today announced that it,has appointed Steven ... and Quality Assurance. Dr. Engel brings to Cytochroma,over ... quality assurance,and will be responsible for directing all ... the Company has appropriate quality,systems in place. He ...
... Accuray,Incorporated (Nasdaq: ARAY ), a global leader in ... chief executive officer, Euan S.,Thomson, Ph.D., is scheduled to ... York City, on Thursday, September 25, 2008 at 9:00 ... the presentation will be available online from the,investor relations ...
... palm plantations will worsen the dual environmental crises of ... protected, warn scientists in the most comprehensive review of ... from the Zoological Society of London and University of ... the role of palm oil production in tropical deforestation ...
Cached Biology Technology:Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance 2Accuray Incorporated's CEO to Speak at UBS Global Life Sciences Conference 2Oil palm plantations are no substitute for tropical rainforests, a new study shows 2Oil palm plantations are no substitute for tropical rainforests, a new study shows 3
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... Milunsky, MD, DSc, has penned a new book focused on ... avoid, prevent, diagnose, predict and treat many genetic disorders. ... learned from many families who benefitted from new advances in ... The book, Your Genes, Your Health: A Critical Family ...
... CORVALLIS, Ore. -- Zoologists at Oregon State University have discovered ... pathogen which is devastating amphibian populations around the world. ... a desperately needed tool for biological control of this deadly ... in a natural setting. The fungus, B. dendrobatidis ...
... Waters Corporation (NYSE:WAT) today recognized the Center for ... a Waters Center of Innovation. In particular, Waters ... Proteomics, and his team for their leadership in the ... In a ceremony at TGen,s headquarters in Phoenix, Ariz., ...
Cached Biology News:BUSM professor authors book on how knowledge about genes and family history can save lives 2Possible biological control discovered for pathogen devastating amphibians 2TGen's Center for Proteomics selected as Waters Center of Innovation 2
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Human Cell Line Slides...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Mouse Cell Line Slides...
Biology Products: